DrugPatentWatch Database Preview
CLINICAL TRIALS PROFILE FOR ACALABRUTINIB
» See Plans and Pricing
All Clinical Trials for Acalabrutinib
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT02029443 | ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (Btk) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia | Active, not recruiting | Acerta Pharma BV | Phase 1/Phase 2 | 2014-01-01 | This study is evaluating the safety and efficacy of a new Bruton tyrosine kinase (Btk) inhibitor, acalabrutinib, for the treatment of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) |
| NCT02157324 | Acalabrutinib in Combination With ACP-319, for Treatment of Chronic Lymphocytic Leukemia | Active, not recruiting | Acerta Pharma BV | Phase 1 | 2014-08-01 | This study is evaluating the safety and efficacy of the combined use of acalabrutinib and ACP-319, for the treatment of chronic lymphocytic leukemia (CLL) |
| NCT02180711 | An Open-label, Phase 1b Study of Acalabrutinib Alone or in Combination With Rituximab in Subjects With Follicular Lymphoma | Active, not recruiting | Acerta Pharma, LLC | Phase 1 | 2014-07-01 | To characterize the safety profile of acalabrutinib alone or in combination with rituximab in subjects with relapsed,refractory,or treatment naive Follicular Lymphoma (FL) |
| NCT02180711 | An Open-label, Phase 1b Study of Acalabrutinib Alone or in Combination With Rituximab in Subjects With Follicular Lymphoma | Active, not recruiting | Acerta Pharma BV | Phase 1 | 2014-07-01 | To characterize the safety profile of acalabrutinib alone or in combination with rituximab in subjects with relapsed,refractory,or treatment naive Follicular Lymphoma (FL) |
| NCT02211014 | An Open-Label, Phase 1b Study of Acalabrutinib With and Without Dexamethasone in Subjects With Multiple Myeloma | Active, not recruiting | Acerta Pharma, LLC | Phase 1 | 2015-02-01 | To characterize the safety profile of acalabrutinib with and without dexamethasone in subjects with relapsed or refractory Multiple Myeloma (MM) |
| NCT02211014 | An Open-Label, Phase 1b Study of Acalabrutinib With and Without Dexamethasone in Subjects With Multiple Myeloma | Active, not recruiting | Acerta Pharma BV | Phase 1 | 2015-02-01 | To characterize the safety profile of acalabrutinib with and without dexamethasone in subjects with relapsed or refractory Multiple Myeloma (MM) |
| NCT02213926 | An Open-label, Phase 2 Study of ACP-196 (Acalabrutinib) in Subjects With Mantle Cell Lymphoma | Active, not recruiting | Acerta Pharma BV | Phase 2 | 2014-09-01 | The purpose of this study is to characterize the safety and efficacy profile of ACP-196 (acalabrutinib) in subjects with relapsed or refractory Mantle Cell Lymphoma (MCL). |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Acalabrutinib
Clinical Trial Locations for Acalabrutinib
Trials by Country
Clinical Trial Progress for Acalabrutinib
Clinical Trial Phase
Clinical Trial Status
Clinical Trial Sponsors for Acalabrutinib
Sponsor Name
